BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 18718581)

  • 1. Clinical use of colony-stimulating factor-1 in ovulation induction for poor responders.
    Takasaki A; Ohba T; Okamura Y; Honda R; Seki M; Tanaka N; Okamura H
    Fertil Steril; 2008 Dec; 90(6):2287-90. PubMed ID: 18718581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating level of macrophage colony-stimulating factor can be predictive for human in vitro fertilization outcome.
    Salmassi A; Mettler L; Jonat W; Buck S; Koch K; Schmutzler AG
    Fertil Steril; 2010 Jan; 93(1):116-23. PubMed ID: 18996518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study.
    Lavery SA; El-Shawarby SA; Turner C; Trew G
    Fertil Steril; 2008 Nov; 90(5):1969-72. PubMed ID: 18166182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
    Serna J; Cholquevilque JL; Cela V; Martínez-Salazar J; Requena A; Garcia-Velasco JA
    Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization.
    Kovacs P; Kovats T; Bernard A; Zadori J; Szmatona G; Kaali SG
    Fertil Steril; 2008 Dec; 90(6):2133-7. PubMed ID: 18177866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Measurement of macrophage colony-stimulating factor during in-vitro fertilization and embryo transfer cycles].
    Quan S; Wan L; Song L
    Zhonghua Fu Chan Ke Za Zhi; 2000 Jan; 35(1):42-4. PubMed ID: 11831950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection.
    Wunder DM; Guibourdenche J; Birkhäuser MH; Bersinger NA
    Fertil Steril; 2008 Dec; 90(6):2203-10. PubMed ID: 18291376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Day 4 versus day 3 embryo transfer: a prospective study of clinical outcomes.
    Pantos K; Makrakis E; Chronopoulou M; Biba M; Perdikaris A; Dafereras A
    Fertil Steril; 2008 Mar; 89(3):573-7. PubMed ID: 17517409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization.
    Morgia F; Sbracia M; Schimberni M; Giallonardo A; Piscitelli C; Giannini P; Aragona C
    Fertil Steril; 2004 Jun; 81(6):1542-7. PubMed ID: 15193474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age.
    Fábregues F; Creus M; Peñarrubia J; Manau D; Vanrell JA; Balasch J
    Fertil Steril; 2006 Apr; 85(4):925-31. PubMed ID: 16580376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.